Breast surgeons expressed strong interest in participating in IceCure's planned post-market study for ProSense® in the treatment of early-stage breast cancer ICE3 study named as one of the "Best Papers of 2024" Cryoablation was mentioned favorably during the ASBrS Presidential Address CAESAREA, Israel, May 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it participated in the American Society of Breast Surgeons (ASBrS) 2025 Annual Meeting on April 30 – May 4, 2025 in Las Vegas. "We co

Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of IceCure's post-market study planIceCure to engage with potential clinical sites, breast surgeons and radiologists for the post-market study including at the upcoming American Society of Breast Surgeons (ASBrS) Annual Meeting ProSense® would become the first-in-class minimally invasive choice—a major advancement in women's health and a new paradigm in breast cancer care as a simple out-patient procedureU.S. sales and distribution team ready to drive sales of ProSense® systems and disposable probes—supporting medical community and patients looking for a new minimally invasive option to l

Two sold-out SBI breast cryoablation courses featured hands-on training with ProSense®IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a specialist in women's imaging and breast cryoablationCAESAREA, Israel, April 28, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation at the Society of Breast Imaging (SBI) 2025 Breast Imaging Symposium which took place April 24-27, 2025 in Colorado Springs, Colorado.   IceCure was a sponsor of the SBI Breast Cryoablation c

Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024. IceCure continues to engage with the U.S. Food and Drug Admin

Interim Data confirm ProSense® cryoablation is highly effective for kidney tumors ≤3 cm and a safe procedure for kidney tumors ≤5 cm in people ineligible for surgery  CAESAREA, Israel, March 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that interim results from the Company's ICESECRET study of cryoablation for patients with small renal masses ("SRM") who cannot be offered kidney preserving surgery were presented at the European Association of Urology Conference in Madrid, Spain whi

CAESAREA, Israel, March 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2024 before the Nasdaq Stock Market opens on Thursday, March 27, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info: Thursday, March 27, 2025, at 10:00 am EDTUS: 1-888-4

IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel, March 20, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it is in continued discussions with the U.S. Food and Drug Administration ("FDA") regarding its De Novo marketing authorization request for ProSense® in early-stage low risk breast cancer with endocrine therapy. The Company now expects the FDA's marketing authorization decision to be reached after the first quarter of 2025. "Given the novelt

This latest IP win rounds out protection for the cryogenic pump in major global market following grants for the same patent in the U.S., Europe and Japan CAESAREA, Israel, March 17, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance for its invention titled "Cryogenic System Connector" from the China National Intellectual Property Administration.     The novel cryogenic pump enables IceCure to bring to market a new generation of cryoablation systems wit

Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® users including Dr. Kizuki Matsumoto and Dr. Eisuke Fukuma Patients who underwent cryoablation compared to breast-conserving therapy (BCT) reported significantly higher satisfaction (71.0±18.6 vs. 56.3±16.5) in the primary outcome with a mean follow-up of 4.2 and 4.0 years, respectivelyData support continued move toward de-escalation of breast cancer treatment from BCT (lumpectomy) to nonsurgical options including cryoablation CAESAREA, Israel, March 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasiv

Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing demand  CAESAREA, Israel, Feb. 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has filed for regulatory approval with the Medical Device Division ("AMAR") of Israel's Ministry of Health for its next-generation single cryoprobe cryoablation system, the XSense™ System and CryoProbes.

Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha

Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel, Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of directors. Mr. Chan has been a private equity executive for the past three decades, managing and leading more than 80 investment projects supporting company growth via funding and synergistic mergers and acquisitions. Since March 2021, he has been the Director of Samena Capital, a prin

CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources. Mrs. Nir Dotan has over two decades of experience in human resources and organizational management. "As the company continues to evolve, we believe investing in our Human Resources function commensurate with an investment in human capital so Mrs. Nir Dotan's appointment is key," stated Eyal Shamir, Chie

6-K - IceCure Medical Ltd. (0001584371) (Filer)

SCHEDULE 13D - IceCure Medical Ltd. (0001584371) (Subject)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

20-F - IceCure Medical Ltd. (0001584371) (Filer)

20-F - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024. IceCure continues to engage with the U.S. Food and Drug Admin

CAESAREA, Israel, March 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2024 before the Nasdaq Stock Market opens on Thursday, March 27, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info: Thursday, March 27, 2025, at 10:00 am EDTUS: 1-888-4

FDA Marketing Authorization Decision on Early Stage-Low Risk Breast Cancer Expected in Q1 2025 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, Nov. 26, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the nine months ended September 30, 2024. Sales of ProSense® consoles and disposable probes increased by 36%. Gross profits increased by 41%, while non-GAAP gross profits grew by 104%. Gross margins increased to 43%, while non-GAAP gr

CAESAREA, Israel, Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2024 before the Nasdaq Stock Market opens on Tuesday, November 26, 2024. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EST on the same day. Conference call & webcast info: Tuesday, November 26, 2024, at 10:00 am EST US: 1-888-407-2553 Israel/Inte

Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, Aug. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2024. Significant Near and Short Term Value Enhancing Catalysts U.S. Food and Drug Administration ("FDA") Medical Device Advisory Committee expected

CAESAREA, Israel, Aug. 13, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2024 before the Nasdaq Stock Market opens on Tuesday, August 20, 2024. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info: Tuesday, August 20, 2024, at 10:00 am EDTUS: 1-888-407-2553Israel/International: +

30% sales growth reflects continued adoption of ProSense® in the U.S. and other global marketsMajor milestones achieved: - Completion of landmark ICE3 trial for breast cancer - Positive final ICE3 trial dataAwaiting FDA Decision Independent studies performed globally continue to demonstrate ProSense®'s efficacy and safety across numerous indicationsConference call to be held today at 11:00 am Eastern TimeCAESAREA, Israel, May 28, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, tod

CAESAREA, Israel, May 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024. The Company will discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT that day. Conference call & webcast info: Tuesday, May 28, 2024, at 11:00 am EDT US: 1-888-407-2553 Isra

CAESAREA, Israel, May 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024. The Company will discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT that day. Conference call & webcast info: Tuesday, May 28, 2024, at 11:00 am EDT US: 1-888-407-2553 Isra

Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense® in breast cancer indication CAESAREA, Israel, April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported sales as of and for the twelve months ended December 31, 2023 increased 26% compared to the twelve months ended December 31, 2022, as the Company continues to transition from a research and development and clinical phase company to a commercial phase company. 2023 Key Financial Highlights:

SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

SC 13G - IceCure Medical Ltd. (0001584371) (Subject)

SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65

Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50